"Biomica Announces Interim Positive Results from Pre-Clinical Studies in its Irritable Bowel Syndrome (IBS) Program"

Biomica Ltd., a clinical-stage biopharmaceutical company, has announced promising interim results from pre-clinical studies in its Irritable Bowel Syndrome (IBS) program. The findings demonstrate the effectiveness of Biomica's live bacterial consortia, BMC426 and BMC427, in alleviating symptoms commonly associated with IBS, such as abdominal pain and abnormal bowel movements. These positive outc..